Interstitial lung disease in patients with connective tissue disease: Subtypes, clinical features and comorbidities in the Western Cape, South Africa.
Interstitial lung disease
connective tissue disease
sub-Saharan Africa
Journal
African journal of thoracic and critical care medicine
ISSN: 2617-0205
Titre abrégé: Afr J Thorac Crit Care Med
Pays: South Africa
ID NLM: 101751995
Informations de publication
Date de publication:
2022
2022
Historique:
accepted:
25
04
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Interstitial lung disease (ILD) is highly prevalent in patients with connective tissue disease (CTD) and is poorly characterised in South Africa. To describe the clinical, serological and radiological features of CTD-ILD and their associations in patients attending a tertiary referral hospital. A cross-sectional study collating clinical, serological and radiological features of CTD-ILD in patients attending rheumatology and respiratory outpatient clinics in a tertiary referral hospital. Of 124 CTD-ILD patients, 37 (29.8%) had rheumatoid arthritis (RA), 32 (25.8%) systemic sclerosis (SSc) and 55 (44.4%) other autoimmune connective tissue diseases (OCTD). Most patients were female (86.3%), of mixed racial ancestry (75.0%), and the median age was 55 years. Nonspecific interstitial pneumonia (NSIP) was the most common ILD pattern (63.7%), followed by usual interstitial pneumonia (UIP) (26.6%). Overall, 60.5% were current or past smokers, 33.1% had previous pulmonary tuberculosis infection, and 75.6% had gastro-oesophageal reflux disease. Patients with RA were older, had similar frequencies of NSIP and UIP, and had significantly better pulmonary function tests than the SSc and OCTD groups. Within three years of CTD diagnosis, two-thirds of the SSc and OCTD patients and almost half of the RA patients had developed ILD. Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT). No case of acute pneumonitis was documented in CTD-ILD patients treated with methotrexate (MTX). We suggest routine HRCT in all newly diagnosed CTD patients, particularly those with SSc and OCTD, where more than two-thirds of the patients had developed ILD within three years of their CTD. The use of MTX was not associated with the development of acute pneumonitis in patients with ILD. Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT).Smoking, environmental toxins, gastro-oesophogeal reflux and previous pulmonary tuberculosis infection were significant comorbidities in CTD-ILD patients.Early screening of ILD with HRCT is recommended, particularly in SSc.Use of MTX before and after ILD diagnosis was not associated with acute pneumonitis.
Sections du résumé
Background
UNASSIGNED
Interstitial lung disease (ILD) is highly prevalent in patients with connective tissue disease (CTD) and is poorly characterised in South Africa.
Objectives
UNASSIGNED
To describe the clinical, serological and radiological features of CTD-ILD and their associations in patients attending a tertiary referral hospital.
Methods
UNASSIGNED
A cross-sectional study collating clinical, serological and radiological features of CTD-ILD in patients attending rheumatology and respiratory outpatient clinics in a tertiary referral hospital.
Results
UNASSIGNED
Of 124 CTD-ILD patients, 37 (29.8%) had rheumatoid arthritis (RA), 32 (25.8%) systemic sclerosis (SSc) and 55 (44.4%) other autoimmune connective tissue diseases (OCTD). Most patients were female (86.3%), of mixed racial ancestry (75.0%), and the median age was 55 years. Nonspecific interstitial pneumonia (NSIP) was the most common ILD pattern (63.7%), followed by usual interstitial pneumonia (UIP) (26.6%). Overall, 60.5% were current or past smokers, 33.1% had previous pulmonary tuberculosis infection, and 75.6% had gastro-oesophageal reflux disease. Patients with RA were older, had similar frequencies of NSIP and UIP, and had significantly better pulmonary function tests than the SSc and OCTD groups. Within three years of CTD diagnosis, two-thirds of the SSc and OCTD patients and almost half of the RA patients had developed ILD. Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT). No case of acute pneumonitis was documented in CTD-ILD patients treated with methotrexate (MTX).
Conclusion
UNASSIGNED
We suggest routine HRCT in all newly diagnosed CTD patients, particularly those with SSc and OCTD, where more than two-thirds of the patients had developed ILD within three years of their CTD. The use of MTX was not associated with the development of acute pneumonitis in patients with ILD.
Key points
UNASSIGNED
Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT).Smoking, environmental toxins, gastro-oesophogeal reflux and previous pulmonary tuberculosis infection were significant comorbidities in CTD-ILD patients.Early screening of ILD with HRCT is recommended, particularly in SSc.Use of MTX before and after ILD diagnosis was not associated with acute pneumonitis.
Identifiants
pubmed: 36034053
doi: 10.7196/AJTCCM.2022.v28i2.213
pmc: PMC9390065
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Conflicts of interest: None.
Références
BMC Pulm Med. 2018 Jun 4;18(1):96
pubmed: 29866093
BMJ. 2016 Feb 24;352:h6819
pubmed: 26912511
Clin Chest Med. 2010 Sep;31(3):479-88
pubmed: 20692540
BMJ Open. 2019 May 5;9(5):e028466
pubmed: 31061059
Front Med (Lausanne). 2019 Oct 23;6:238
pubmed: 31709258
Rheumatology (Oxford). 2018 Feb 1;57(2):255-262
pubmed: 28379478
Best Pract Res Clin Rheumatol. 2016 Oct;30(5):870-888
pubmed: 27964793
Curr Opin Rheumatol. 2016 May;28(3):236-45
pubmed: 27027811
Clin Immunol. 2018 Jan;186:71-73
pubmed: 28923440
Nat Rev Rheumatol. 2021 Feb;17(2):79-80
pubmed: 33408337
Biomed Res Int. 2018 May 8;2018:6930297
pubmed: 29854780
Semin Respir Crit Care Med. 2019 Apr;40(2):208-226
pubmed: 31137061
Rheumatol Int. 2010 Aug;30(10):1317-24
pubmed: 19844720
Chest. 2017 Dec;152(6):1283-1295
pubmed: 28552544
Radiol Med. 2018 Sep;123(9):655-663
pubmed: 29687210
Rheumatol Int. 2018 Apr;38(4):657-662
pubmed: 29185086
PLoS One. 2014 Jun 06;9(6):e98824
pubmed: 24905449
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Semin Respir Crit Care Med. 2019 Apr;40(2):194-207
pubmed: 31137060
Clin Rheumatol. 2021 Sep;40(9):3455-3460
pubmed: 32803569
Chest. 2014 Aug;146(2):422-436
pubmed: 24576924
Expert Rev Clin Immunol. 2018 Jan;14(1):69-82
pubmed: 29202589